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Specific IgA Enhances the 
Transcytosis and Excretion of 
Hepatitis A Virus
Natalie A. Counihan† & David A. Anderson
Hepatitis A virus (HAV) replicates in the liver, and is excreted from the body in feces. However, the 
mechanisms of HAV transport from hepatocytes to the gastrointestinal tract are poorly understood, 
mainly due to lack of suitable in vitro models. Here, we use a polarized hepatic cell line and in vivo 
models to demonstrate vectorial transport of HAV from hepatocytes into bile via the apical cell 
membrane. Although this transport is specific for HAV, the rate of fecal excretion in inefficient, 
accounting for less than 1% of input virus from the bloodstream per hour. However, we also found that 
the rate of HAV excretion was enhanced in the presence of HAV-specific IgA. Using mice lacking the 
polymeric IgA receptor (pIgR−/−), we show that a proportion of HAV:IgA complexes are transported via 
the pIgR demonstrating a role for specific antibody in pathogen excretion.
Hepatitis A virus (HAV) is an orally transmitted hepatotropic picornavirus that first infects the mucosa of the gas-
trointestinal tract. Once this epithelium is penetrated, blood-derived HAV presumably reaches the liver via portal 
circulation. Antigen is first detected in liver-residing Kupffer cells 1–3 weeks post experimental inoculation, fol-
lowed shortly by infection of hepatocytes1–3. Viremia is present from 2 weeks post-infection, and can persist for 
4 weeks to over a year1,4. Following extensive replication in hepatocytes, HAV is excreted from the body in feces, 
but the mechanism of transport remains ambiguous. Interestingly, HAV circulating in blood is closely associated 
with a lipid membrane, perhaps as an antibody-evasion mechanism, but virus shed in feces lacks this membrane 
for reasons unknown5. In order to better understand HAV trafficking pathogenesis, suitable in vitro models are 
required to reflect the highly polarized nature of intestinal and hepatic tissue.
Cell polarity is a property of epithelial tissue, and is achieved by the asymmetrical expression of proteins on 
apical (luminal) and basolateral (vascular) surfaces. This cellular orientation and organization is fundamental for 
the physiological functions of mucosal and hepatic tissues, including the absorption and secretion of hormones, 
lipids and proteins. In hepatocytes, the canalicular membrane serves as the apical pole and leads directly into the 
biliary canaliculus. Thus, any substrate exported from this membrane may traverse the gastrointestinal tract in 
bile. Basolateral cargo are exported into the space of Disse and the hepatic sinusoids which have extensive con-
nectivity to blood vessels.
There are several in vitro models of polarized tissue including MDCK and Caco-2 cells, both of which display 
simple, columnar orientation of polarity amenable to in vitro manipulations. However, these non-hepatic models 
are not appropriate for studies with hepatotropic viruses, as hepatocytes have unique and complex mechanisms 
for polarized transport. In addition, hepatocytes do not display columnar orientation of polarity that is typical of 
mucosal tissue. Rather, they display a complex three-dimensional structure that is not amenable to in vitro culture 
using normal methods. Further, primary hepatocytes are technically difficult to grow, and rapidly lose their polar-
ization upon culture6. A clone of HepG2 cells have been identified that maintains the functional characteristics 
of hepatocytes, yet displays the morphology typical of columnar epithelia, representing the first in vitro model 
of polarized hepatocytes7. This HepG2-derived N6 clone of cells was used to investigate trafficking of HAV from 
polarized hepatocytes. It was shown that progeny HAV was almost exclusively exported via the basolateral mem-
brane, suggesting that infected hepatocytes excrete virus into the blood rather than the bile as expected. Whilst 
these finding readily explain the viremia observed in the actuate phase of the disease, they do not account for high 
titer virus shed in feces. Thus a fundamental question about HAV pathogenesis still remains: how does the virus 
reach the gastrointestinal tract for enteric excretion? In this paper we investigate a mechanism for HAV export 
using N6 cells as a model for polarized hepatocytes.
Centre for Biomedical Research, Burnet Institute, Melbourne, Victoria, Australia. †Present address: School of 
Medicine, Deakin University, Geelong, Victoria, Australia. Correspondence and requests for materials should be 
addressed to N.A.C. (email: n.counihan@deakin.edu.au)
Received: 21 August 2015
Accepted: 02 February 2016
Published: 25 February 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:21855 | DOI: 10.1038/srep21855
Infection with HAV induces both IgG and IgM antibodies, but also a prolonged IgA response2,8. IgA is an 
essential component of mucosal immunity, and is transported through cells via a well-characterized secretory 
pathway via a specific receptor, the polymeric immunoglobulin receptor (pIgR). This type I transmembrane pro-
tein has an affinity for IgM or polymeric IgA (pIgA). IgA can function to prevent attachment of pathogens, par-
ticipate in intracellular neutralization of viruses, and assist in immune elimination by clearing antigen complexes 
from systemic circulation (reviewed in9). Blood to bile transport of IgA through hepatocytes has been described 
for rats and mice10–12, but studies in humans using a suitable in vitro model have been inconclusive13–17.
IgA has long been implicated in HAV infection. HAV-specific IgA has been detected in the feces and serum 
of infected hosts as early as 4 days after the onset of symptoms, and can persist for three years or longer18–21. 
Additionally, HAV-specific IgA has been partially associated with virus purified from feces2,8, thus may be impli-
cated in virus excretion. Considering the close association of IgA with HAV infection, we sought to investigate the 
contribution of IgA to HAV transport and export. Taking into account the normal secretory pathway of IgA is in 
the basolateral to apical direction, we hypothesized that blood to bile transport of HAV may be enhanced in the 
presence of specific IgA. The aim of this study was to explore the mechanism for HAV export from hepatocytes, 
and to determine the role of specific IgA in this process using both in vitro and in vivo models.
Results
HAV is trafficked from basolateral to apical membranes in vitro. In this study, we used a previously 
characterised model of columnar polarized hepatocytes as an in vitro model to investigate transcytosis of HAV.
To measure active transport of virus in the basolateral to apical direction, 106 focus-forming units (FFU) of 
HAV was added to the basolateral side of cultures and incubated at 37 °C or 4 °C for 2 h. In addition to HAV, feline 
calicivirus (FCV) was included in the same inocula as a control for non-specific viral transport. The most baso-
lateral to apical transport was observed in HAV cultures that were warmed to 37 °C, suggesting active transport 
of HAV (Fig. 1A).
HAV is trafficked from basolateral to apical membranes in vivo. In vitro results indicate that HAV 
shows polarized movement towards the apical pole by a temperature-sensitive mechanism. Although these find-
ings were obtained using a polarized cell line, they cannot be directly translated into in vivo situations, as cell 
polarity within the liver is invariably more complex than our cell culture model. Additionally, it is difficult to 
quantify the proportion of completely polarized cells, thus results vary considerably between experiments.
To overcome these limitations, these experiments were extended using an in vivo system. A mouse model 
was selected as they are not the natural hosts for HAV, thus can be used to study virus transport independent of 
infection22 and have previously been used to study basolateral to apical transport of hepatic IgA10,23. Virus can be 
delivered directly to basolateral membranes via intravenous (iv) injection of the tail vein. It was hypothesized that 
HAV would be trafficked to the apical pole of hepatocytes, secreted with bile into the gastrointestinal tract, and 
then excreted in feces. To investigate, mice were injected with HAV and at regular intervals fecal samples were 
collected and titrated for HAV infectivity. Significant quantities of HAV were recovered from all samples collected 
between 2 and 16 hours post-injection (Fig. 1B). As peak virus titers were observed after 4 h, subsequent exper-
iments were restricted to this time frame. To investigate specificity of basolateral to apical virus transport, feces 
were collected from mice injected with either HAV or FCV and virus titers determined (Fig. 1C). Bile and blood 
samples were also collected for HAV titration and processed as described in Materials and Methods. Basolateral 
to apical trafficking was specific to HAV, as FCV was not detected in bile or fecal samples (Fig. 1C). Importantly, 
the serum concentrations of FCV and HAV were not significantly different (p = 0.5281), confirming that each 
group received comparable inocula.
Fecal and biliary excretion rates of HAV and FCV. In Fig. 1C, fecal virus titers show mean tires per 
ml of virus, which equates to 1g of feces. To determine the rate at which virus was excreted from mice, the aver-
age mouse defecation rate per hour was determined over a 12h period (71 mg feces/h; Fig. 1D) and virus titers 
were multiplied by this figure to determine the amount of virus excreted per hour. This was then expressed as 
a percentage of input virus (Fig. 1E). The amount of bile excreted per mouse was calculated using bile excre-
tion rates previously published (305 μ l/100 g of body weight per hour24) Individual mice were weighed and their 
weight-adjusted bile excretion rate determined. This rate was then used to calculate biliary excretion rates per 
hour, which was then expressed as a percentage of input virus (Fig. 1E). Excretion of HAV from feces and bile 
were strikingly similar (0.80–0.83% of input virus per hour), with limited FCV detected. To ensure the lack of 
FCV in feces and bile was not due to inactivation, samples were spiked with known quantities of HAV and FCV 
and close to all the input HAV and FCV was recovered (Fig. 1F). Together, the data from Fig. 1 supports the 
hypothesis that HAV is transported from the basolateral to apical membranes in vitro and in vivo (although 
somewhat inefficiently), via a specific, temperature-dependent mechanism of transcytosis. These data represent 
evidence of HAV being excreted from hepatocytes via an indirect mechanism.
Characterization of HAV-specific IgA antibodies. IgA has a strong association with HAV, and can 
enhance infection of enterocytes8,25. Additionally, IgA is transported through epithelia into secretions in the same 
direction as HAV (basolateral to apical) to transport IgA from the vascular system into bile. Due to the close 
association of IgA with HAV and their common intracellular trafficking pathways, we investigated the effect of 
specific IgA on HAV transcytosis. pIgR-mediated transcytosis of IgA has been extensively studied as a model for 
basolateral to apical transcytosis, however, the majority of data was obtained using MDCK cells transfected with 
rabbit pIgR26,27. IgA transport mechanisms have been described for rodent hepatocytes but parallel studies with 
humans are less well described and localization of human pIgR was difficult to demonstrate in non-polarized 
cells13,15–17. Investigations of hepatic IgA transport were performed using our polarized N6 model of hepatocytes. 
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Before investigating transcytosis, we first confirmed the presence of pIgR in polarized N6 cells by immunoblot-
ting (Fig. 2A) using Caco2 cells and recombinant pIgR (rpIgR) as positive controls. A species similar in size to 
rpIgR representing full length pIgR was observed in N6 and Caco2 cells, but not irrelevant BSC-1 cells (data not 
shown). RT PCR was used to confirm mRNA expression, and validated by DNA sequencing (data not shown). 
Once pIgR expression was confirmed, HAV-specific IgA antibodies were sourced to investigate IgA-mediated 
trafficking of HAV including a previously characterised anti-HAV monoclonal antibody 1.19328,29. An additional 
IgA antibody was induced by immunizing mice with inactivated HAV (see Materials and Methods). Both anti-
bodies were reactive to HAV antigen by ELISA (data not shown) and contained significant proportions of dimeric 
IgA and higher order structures (Fig. 2B, about 50% dimeric IgA). Under reducing conditions, a single band 
representing IgA heavy chains was observed for each antibody. To determine the neutralizing capacity of each 
Figure 1. HAV is specifically trafficked from basolateral to apical membranes. (A) In vitro trafficking of 
HAV in polarized N6 cells. HAV and FCV were added to the basolateral compartment of polarized cultures, 
incubated at the indicated temperature and apical supernatants titrated for infectivity after 2 h. Data show mean 
rate of transport as a percentage of input virus+ /− SEM (n = 3 (FCV) or 12 (HAV). (B) In vivo transcytosis of 
HAV. To demonstrate blood to bile transport, feces were collected from HAV-injected mice and the indicated 
time point post-injection and the HAV titer determined. Data show mean HAV titer+ /− SEM (n = 4).  
(C) Transcytosis is specific for HAV. To compare transport of HAV and FCV, groups of mice were injected with 
either virus and samples collected at the indicated time points. Data show average viral titers of HAV (grey) and 
FCV (black)+ /− SEM (n = 6). (D) Average excretion rates of C57/Black6 mice. Feces were collected from age- 
and species-matched mice at the indicated times to determine fecal excretion rates. Data show average weight 
at each time+ /− SEM (n = 6). The dotted line shows the mean weight across all timepoints. (E) Excretion rates 
of HAV and FCV. The rate of HAV (grey) and FCV (black) excreted in bile and feces was determined from 4 h 
samples. Data show mean rate of transcytosis as a percentage of input virus (n = 6). (F) Recovery of HAV and 
FCV in feces and bile. Samples were obtained from non-injected control mice and spiked with equal amounts 
(106 FFU or PFU) of HAV (grey) and FCV (black). Samples were incubated at 4 °C and titrated to determine 
percentage recovery+ /− SEM (n = 4).
www.nature.com/scientificreports/
4Scientific RepoRts | 6:21855 | DOI: 10.1038/srep21855
antibody, equal amounts were mixed with virus for 1 h, and then titrated for infectivity (Fig. 2C). 1.193 antibody 
was found to be a neutralizing antibody, and infectious virus could only be recovered after acid treatment (see 
Materials and Methods).
In vitro transcytosis of IgA. To demonstrate transcytosis of IgA, HAV antibody 1.193 was added basolater-
ally to polarized cultures and titrated for IgA by ELISA. In 3 experiments, an average of 1.53% (+ /− SEM of 0.27) 
of input antibody was detected in the apical compartment after 1 h compared with 0.27% (+ /− SEM of 0.03) of 
dextran. These results indicate that 1.193 is transported preferentially over dextran, but somewhat inefficiently, 
perhaps due to 1.193 containing a significant amount of monomeric IgA. To determine if pIgR was responsible 
for this transport, pIgR was blocked by pre-incubation with anti-pIgR antibody and the rate of 1.193 transcytosis 
determined (Fig. 2D). Addition of anti-pIgR antibody reduced IgA transcytosis to <15% of non-treated samples, 
Figure 2. Transcytosis of IgA. (A) Western blot of pIgR from N6 and Caco2 cells. To confirm protein 
expression of pIgR, lysates of N6 and Caco-2 cells were probed with pIgR-specific antibody; recombinant 
pIgR (rpIgR) served as a positive control. A single specific band of similar size to rpIgR was observed for both 
cell types. (B) Separation of IgA MAbs. HAV antibodies and nsIgA were subjected to electrophoresis under 
reducing and non-reducing conditions. Monomeric and dimeric IgA were observed for all 3 antibodies.  
(C) Neutralization of IgA antibodies. Equal amounts of HAV were incubated with indicated amounts of 
antibody and titrated for infectivity by FIFA. Foci of infection were counted to determine HAV infectivity, and 
are shown for each sample in FFU/ml. 1.193 samples were acid treated to prior to titration recover infectious 
virus. (D) 1.193 transcytosis is inhibited with anti-pIgR antibody. Basolateral membranes were pre-incubated 
with 2.5 μ g of anti-pIgR antibody or isotype control for 1 h. 1.193 was then added and the rate of transcytosis 
determined after 1 h. The reduction in IgA transcytosis with antibody was determined relative to no treatment 
(n = 3). (E) In vitro HAV transcytosis is enhanced with 1.193 antibody. Virus-antibody complexes were 
incubated, and then added to the basolateral membrane of polarized cultures. Supernatants were collected 
after 2 h and titrated for HAV infectivity. 1.193-containing supernatants were acid-treated prior to titration 
(n = 5–10). For both graphs, error bars show SEM and statistical significance was determined using an unpaired 
t-test.
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suggesting that a significant amount of transcytosed IgA is mediated by pIgR. 3H1 and 1.193 antibodies were 
next complexed with HAV and added to basolateral compartments and the rate of basolateral to apical transport 
of HAV determined (Fig. 2E). For these experiments, non-specific IgA (nsIgA) was used as a control. Results 
indicate that the most efficient trafficking of HAV was observed when virus was complexed with 1.193 antibody 
(p = 0.02). There was no significant difference in the amount of HAV present when complexed with either 3H1 
or nsIgA.
HAV fecal excretion is enhanced with IgA. As results from in vitro experiments demonstrated enhanced 
transcytosis with specific antibody (Fig. 2E), trafficking of HAV:IgA complexes was next investigated in vivo to see 
if transcytosis efficiency was altered in the presence of specific IgA. Pre-incubated HAV:IgA complexes were deliv-
ered to the liver of C57/Black6 mice via iv injection. In pilot experiments, recovery of virus from HAV: 1.193 com-
plexes was poor due to the neutralizing nature of this antibody despite treatment with acid to disrupt the complex 
(< 5% of input virus was recovered, data not shown). However, HAV was efficiently recovered from fecal samples 
spiked with 3H1 both with and without acid treatment (Fig. 3A), so this antibody was used for subsequent exper-
iments. Feces and bile were collected 4 h post-injection and excretion rates calculated using previously described 
methods. Interestingly, the amount of HAV recovered from feces of mice receiving complexed virus was signifi-
cantly higher than those receiving virus alone, but these effects were not significant in bile (Fig. 3B).
HAV:IgA export is mediated by IgA secretory pathway. To further investigate HAV transcytosis 
with IgA, knockout mice (KO) lacking the IgA receptor (pIgR−/−) were used30. As these mice do not express a 
Figure 3. In vivo transcytosis of HAV is enhanced in the presence of specific IgA and is mediated by pIgR. 
(A) HAV can be recovered from fecal samples spiked with HAV:3H1 complexes. Fecal samples were spiked 
with HAV:3H1 complexes and HAV recovered with and without acid treatment. Data show average HAV 
titers after recovery and recovery rate when compared with pre-treatment samples. (B) In vivo transcytosis of 
HAV:3H1. The mean rate of HAV excretion in mice injected with HAV (grey) or HAV:3H1 complexes (black)
was determined after 4 h from feces and bile. (C) HAV:IgA transcytosis is mediated by pIgR. The rate of HAV 
fecal excretion was determined in WT and KO mice injected with either HAV:3H1 or HAV:nsIgA complexes. 
For both graphs, n = 6, error bars show SEM and an unpaired t-test was used to compare rates of excretion.  
(D) Rates of HAV transcytosis. Excretion rates for all groups of mice at 4 h are compared (nt = not tested).
www.nature.com/scientificreports/
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functional receptor for IgA in intestinal or hepatic tissues, IgA transcytosis is reduced30,31. Despite lacking a recep-
tor, minimal amounts of IgA were detected in feces and bile (Supp Fig. 1). To investigate HAV transcytosis, groups 
of WT and KO mice were injected with HAV complexed with either nsIgA or 3H1 and feces collected after 4 h 
(Fig. 3C). KO mice receiving HAV:3H1 complexes had a significantly lower rate of HAV transcytosis compared 
with WT mice. Figure 3D shows bile excretion rates for KO mice, and summarises all the transcytosis experi-
ments presented in Figs 1–3. HAV alone is transcytosed in feces at a peak rate of 0.83% of virus per hour, but this 
is increased about 11-fold with the addition of 3H1, and similar trends are observed for bile. When compared 
with WT mice, KO mice show a significant reduction in biliary 3H1 transcytosis (0.08% per hour, compared with 
5.48% per hour), but smaller differences are observed in feces. Similarly, in HAV: 3H1-injected WT mice, compa-
rable amounts of HAV were excreted in bile and feces, but KO mice show a marked reduction of HAV secretion in 
bile compared with feces. It must be noted that the excretion rate of virus complexed to nsIgA injected into WT 
mice (0.16) and KO mice (0.08) was unexpectedly lower than that of virus alone (0.83%). As it is not likely that 
HAV is forming complexes with nsIgA, the reduced excretion rate may be due to steric hindrance from the IgA, 
or due to the sample sizes used in the experiments (n = 6).
Discussion
The work described here provides experimental evidence of HAV secretion into feces. Interestingly, HAV is first 
sorted to the basolateral membrane prior to export at the apical pole7, a seemingly complicated route for secre-
tion, but consistent with default sorting pathway of hepatocytes32–36. The presence of virus at the basolateral 
membrane may readily explain the viremia observed during acute illness1,37. A recent study has described two 
distinct populations of HAV that exist during infection; exosome-like enveloped HAV circulating in blood, and 
non-enveloped virus that is shed in feces5. The observation of two distinct viral species is interesting, and has 
implications for the current study. We hypothesize that virus secreted basolaterally from hepatocytes7 is a mixture 
of enveloped and non-enveloped virus and that the pool of naked virus is transcytosed for secretion into bile and 
excretion in feces. The remaining enveloped virus pool is then able to circulate in blood to facilitate spread pro-
tected from neutralising antibody. One limitation of our study is that the viral inoculum that contains a mixture of 
enveloped and non-enveloped virus5 was delivered to hepatocytes via the blood, and not as basolaterally secreted 
virus, but this was unavoidable.
In this study, we observed blood to bile transport of HAV but fecal excretion rates were low, thus may not 
account for the large amount of virus shed in feces. The apparent inefficiency of HAV export observed in our 
system prompted us to further investigate virus transcytosis. We hypothesized that virus may be transported 
more efficiently via a carrier-mediated mechanism, as has been suggested for HAV export from enteric epithelia29. 
We first investigated IgA as a potential candidate for enhancing HAV export, as this ligand is transported from 
basolateral to apical membranes in epithelial cells, including hepatocytes. Additionally, increased accumulation 
of HAV RNA is observed in the liver when the virus is complexed with IgA compared to uncomplexed virus22. 
Finally, HAV-specific IgA is associated with HAV in virus in feces, suggesting a role for IgA in HAV infection2,8,38.
Having demonstrated hepatic transcytosis of IgA, we next investigated HAV:IgA transcytosis. Using in vitro 
and in vivo models, we show that fecal virus excretion is enhanced from 0.83% to 9.16% in the presence of spe-
cific antibody, but no enhancement was observed with control antibody (Fig. 3D). Studies using pIgR−/− mice 
showed limited transcytosis of HAV:IgA (Fig. 3C,D), suggesting that HAV transport in pIgR-dependent. Results 
suggest that HAV may be transcytosed through hepatocytes to the apical pole via 2 mechanisms, via the default 
pIgR-mediated pathway, and by a pIgR-independent mechanism. Further work needs to be completed to investi-
gate these mechanisms further.
Export of HAV from hepatocytes was inefficient in our hands, although a significant increase in fecal virus was 
observed in the presence of IgA. The normal function of IgA is to limit pathogen invasion and spread, commonly 
by preventing attachment to epithelia, or by neutralizing intracellular pathogens39–41. IgA has previously been 
shown to aid in the excretion of antigens42–44, but this has not been demonstrated for whole viruses. Thus, the 
findings in this study are interesting, as IgA is implicated in the export of infectious virus bound to virus-specific 
antibody, thereby facilitating further transmission of the virus. Despite our findings, the contribution of IgA to 
HAV secretion is still unclear. Although induction of IgA is rapid compared with the IgG response21, a significant 
proportion of HAV is excreted into feces prior to antibody production45, thus a considerable amount of virus 
shedding occurs in the absence of IgA. In one study, a bi-phasic pattern of fecal excretion was observed in 2 out of 
3 animal subjects45, suggesting that excretion may be enhanced once a robust IgA response is established, however 
this hypothesis requires further examination. Despite the ambiguity over the contribution of IgA to virus excre-
tion, it is clearly important as fecal HAV has been observed coated with sIgA8. Thus our results shed some light on 
the complex transmission of HAV and present an interesting example of a virus exploiting a cellular mechanism 
for enhanced transmission.
Materials and Methods
Ethics statement. All animal experiments were conducted in accordance with the NHMRC Australian code 
of practice for the care and use of animals for scientific purposes (7th edition, 2004) and were approved by the 
AMREP animal ethics committee (project number E/0515/2006/F).
Culture of polarized cells. Polarized N6 cells were cloned from HepG2-derived C3A cells (American Type 
Culture Collection) and maintained as previously described7. For in vitro transcytosis experiments, a single cell 
suspension containing 5 × 104 N6 cells were seeded onto Transwell-COL porous tissue culture inserts (Costar) 
with 3.0 μ m pore size and incubated at 37 °C for up to 24 days, using Williams medium E and supplemented with 
10% FCS, 100 μ g/ml streptomycin, 100 U penicillin, 2 mM glutamine, 10 mM tris and 1% dimethyl sulfoxide.
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Assays for cell polarity. After 14 days in culture, cells were tested often to assess polarity using a variety 
of methods. Human hepatocytes produce albumin that is secreted basolaterally into blood, thus the proportion 
of albumin present in basolateral supernatants of each culture was used as an indicator of polarity, as has been 
described previously7. Briefly, an ELISA was used to detect human albumin in apical and basolateral chambers. 
Cultures were deemed polarized if > 85% of albumin was basolaterally secreted. Additionally, diffusion of a small 
molecule (10kDa dextran) was used as a marker of polarity, as tight junction formation in polarized cells should 
restrict movement of such molecules. The rate of Alexa 680-labelled dextran transport was determined by adding 
10 μ l to basolateral compartments and regularly sampling apical supernatants. The intensity of infrared fluo-
rescence of triplicate samples was then measured using the Odyssey infrared imager and used to determine the 
percentage diffusion per hour. Cells were deemed sufficiently polarized if dextran trafficking was < 0.30%/hr. 
Monolayer integrity was also assessed by immunofluorescent staining for tight junction protein Zo-1, as previ-
ously described7.
Viruses and infectivity assays. HAV strain HM175A.2 was propagated in BSC-1 cells and purified and 
quantitated as previously described7,46. FCV was propagated in CRFK cells and purified and titrated as previously 
described7.
IgA antibodies. Antibodies utilized included previously characterized anti-HAV IgA 1.193 antibody (kindly 
provided by Prof. S. Lemon)47 and purified non-immune mouse IgA (Sigma). Anti-HAV IgA 3H1 was obtained by 
immunizing Balb/C mice with two doses of 107 FFU equivalents of formaldehyde-inactivated HAV at four-week 
intervals via the intraperitoneal route. Mice were bled four weeks post-injection, and sera tested for reactivity by 
ELISA to detect total antibody. Splenic fusion and hybridoma cloning was performed at The Walter and Eliza 
Hall Institute (Melbourne, Australia). Supernatants were screened for reactivity by ELISA. Antibody isotype was 
determined using IsoStrip (Roche).
Characterization of pIgR and IgA antibodies. To investigate expression of pIgR in N6 and Caco2 cells, 
clarified lysates were separated by SDS-PAGE and probed with anti-human pIgR (R&D Systems) by western 
blot. Recombinant pIgR (R&D Systems) was used as a positive control. IgA antibodies were characterized by 
Western Blot using a 4–15% precast gradient gel under reducing and non-reducing conditions. To determine the 
neutralizing capacity of IgA antibodies, 1–10 μ g of antibody were mixed with HAV for 1 h at 37 °C and titrated 
for infectivity by FIFA. To recover infectious virus from HAV neutralized with 1.193, complexes were treated at 
pH 1.5 (using 0.1 M glycine pH 1.0) for 1 h. Post -incubation, complexes were returned to pH 6.0 with 1 M NaOH, 
and titrated for infectivity. To block pIgR, 2.5 μ g of anti-human pIgR or isotype control were incubated in the 
basolateral compartment for 1 h, then IgA added for transcytosis experiments.
ELISA for HAV IgA antibody. Maxisorb microtiter plates were coated overnight at 4 °C with 0.1% puri-
fied, inactivated HAV antigen (BioDesign) in 0.1 M NaHCO3 (pH 9.6) and blocked with 0.5% casein in PBS. 
HAV-specific total antibody was detected with anti-mouse HRP. Total IgA was detected with goat anti-mouse IgA 
HRP. Color development was observed with the addition of tetramethylbenzidine, and stopped with 0.5 M H2SO4. 
Optical density was measured at 450 nm and 620 nm.
In vitro transcytosis experiments. For HAV transcytosis experiments, virus was diluted 10-fold in 
serum-free (SF) media to a final titer of 106 FFU or PFU per well, chloroform extracted and further diluted to 
2.6ml total volume with media containing 1% serum. The inoculum was added to the basolateral domain of 
polarized cultures and incubated at 37 °C or 4 °C for 2 h. Following incubation supernatants were removed and 
culture replaced with fresh media containing 1% serum. Supernatants were titrated for infectivity by FIFA and 
plaque assay to determine titers of HAV and FCV, respectively. The rate of HAV or FCV transcytosis was deter-
mined as a percentage of input virus per hour. For IgA transcytosis experiments, 10–25 μ g of antibody was diluted 
in 2.6 ml of serum-free media and added to the basolateral compartment of polarized cultures. Supernatants were 
collected after 2 h to determine the rate of transcytosis. For HAV-IgA transcytosis experiments, 106 FFU of HAV 
was incubated with 10–25 μ g of 1.193, 3H1 or nsIgA for 1 h at 37 °C and then applied to the basolateral mem-
brane of polarized N6 cultures as described previously. Supernatants were titrated for HAV infectivity via FIFA. 
Supernatants containing 1.193 were acid-treated prior to titration, as described previously.
In vivo transcytosis experiments. To demonstrate transcytosis in vivo, 8–10 week old C57/Black 6 (WT) 
mice were injected iv with 100 μ l of virus (106 FFU/PFU of HAV or FCV diluted 10-fold in PBS) via the tail 
vein48,49. For experiments with IgA, HAV-antibody mixtures were incubated for 1 h at 37 °C prior to each assay. 
Infectious HAV was recovered from 1.193-containing samples by acid treatment, as described earlier. In addi-
tion, pIgR deficient mice were used in parallel to determine the contribution of IgA to HAV transcytosis. These 
aged-matched KO mice (pIgR−/−) were generated on a C57/Black6 background and were kindly provided by Dr 
O. Wijburg (University of Melbourne, Melbourne Australia)30.
At regular intervals post-injection, fecal samples were collected in PBS + 0.1 mg/ml soybean trypsin inhibitor 
to make a 10% (w/v) suspension, vortexed and spun at 14000 rpm/4 °C/10 min. Supernatants were then frozen 
until titration. Post-mortem, bile was collected using a 1 ml insulin syringe directly from the gall bladder and 
diluted 10-fold in SF media. Blood was collected via cardiac bleed, left to clot, spun at 8000 rpm/4 °C/10 min and 
serum collected. For titration, all samples were diluted ten-fold in media with 1% serum, and titrated for infectiv-
ity by FIFA (for HAV) and plaque assay (for FCV). Virus titers for each sample were determined, and expressed as 
FFU or PFU per ml of sample after correcting for dilutions performed during sample preparation. Using rates of 
excretion for feces and bile, the amount of HAV and FCV excreted per ml or per gram per hour was determined24. 
It should be noted that these calculations have limitations, as calculations were based on the assumption that each 
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mouse received 100% of the inoculum. However, considering the small inocula size (100 μ l), there was most likely 
variation in the amount of virus delivered to each animal leading to larger variability in experiments. Also, as it 
was impractical to collect all the feces from each mouse for each timepoints, it was also assumed that the fecal 
excretion rate estimated in the pilot experiment was applicable to all further experiments.
Statistical analysis. Statistical analysis (unpaired two-tailed t-test) of data were performed using GraphPad 
Prism Software. For all in vitro data, n refers to the number of times the experiment was independently performed 
using different cultures.
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